I K-ATP , which were first described in the heart, couple cellular metabolic status to the electrical excitability of the plasma membrane. Patch-clamp studies have also demonstrated their presence on pancreatic ␤, skeletal, smooth muscle, and brain cells (1) . Antagonist and agonist drugs have been described that interact with these channels. Thus, the hypoglycemic sulfonylureas, such as glyburide, act as specific antagonists and inhibit I K-ATP opening induced by metabolic inhibition or KCOs. KCOs represent a structurally diverse class of compounds that open I K-ATP and thus have broad therapeutic potential. However, effective therapies for nonvascular indications are likely to require the introduction of tissue-selectivity because vasorelaxation and hypotension would produce unacceptable side effects. Indeed, cardioprotective KCOs structurally related to cromakalim have recently been described that have the cardioprotective potency of cromakalim but exhibit markedly diminished vascular activities (2) . The KCO diazoxide also seems to be somewhat unique because it activates pancreatic ␤ cell I K-ATP but functions, like tolbutamide, to inhibit cardiac channels (3) . The basis for this tissue specificity is currently unknown but may relate to differences in I K-ATP isoforms.
Skeletal muscle contains a large abundance of I K-ATP , which can be activated by KCOs such as levcromakalim (4) and pinacidil (5) . Treatment with pinacidil mimicked the effects of ischemic preconditioning (6) , which suggests that I K-ATP activation may be a protective mechanism during skeletal muscle anoxia. Treatment with the KCOs cromakalim and P1075 improved force recovery of rat skeletal muscle exposed to anoxia and reperfusion (7) . Patch-clamp studies of mammalian skeletal muscle cells led to the development of models of I K-ATP that contain stimulatory and inhibitory nucleotide regulation sites (5, 8) . Pinacidil is thought to open skeletal muscle I K-ATP by interaction with these sites (5) . To examine the biochemical interaction of KCOs with skeletal muscle sites, we conducted binding studies using the potent KCO [
3 H]P1075. Bray and Quast (9) and Quast et al. (10) used this radioligand to define a sulfonylurea-sensitive KCO binding site in endothelium-denuded rat aortic rings, which correlated with sites mediating vasorelaxation. The challenge of the current work was to define conditions that allowed KCO binding to skeletal muscle membranes because homogenization of cells or tissues results in loss of specific binding sites (9, 11) . Thus, binding studies, to date, have necessitated the use of tissue rings (9, 10) or large numbers of viable cells (11) .
I K-ATP are thought to consist of a complex of proteins, including ATP binding cassette protein or proteins (SUR) and inward rectifier protein or proteins (12) . They are modulated by nucleotides (13) and phosphorylation states (14) . In the current study, we examined the effects of these parameters on KCO binding and describe the pharmacological characteristics of a [ 3 H]P1075 binding site on rabbit skeletal muscle membranes.
Materials and Methods
Skeletal muscle membrane preparations. Rabbits (2.5-3 kg) were anesthetized with sodium pentobarbital, and their hindlimbs were dissected and weighed. Tissue was minced with scissors into 5 volumes (w/v) of 20 mM NaHCO 3 and 0.1 mM phenylmethylsulfonyl fluoride and homogenized using a Brinkmann Instruments Polytron homogenizer (4 ϫ 10 sec, setting 7; Westbury, NY). The homogenate was centrifuged at 3,500 ϫ g for 15 min at 4°, and the supernatant was filtered through cheesecloth. The filtrate was recentrifuged at 100,000 ϫ g for 60 min, and the pellet was washed into 50 mM Tris⅐HCl, pH 7.4. The membranes were resuspended in 25 ml of 50 mM Tris⅐HCl, pH 7.4, at a protein concentration of 8-11 mg/ml and stored frozen in aliquots at Ϫ80°.
Skeletal muscle membranes were further purified for [ 3 H]P1075 localization studies as follows. Skeletal muscle (50 g) was homogenized for 1 min in 250 ml of 0.3 M sucrose and 5 mM imidazole, pH 7.4, in a Waring blender at maximum speed. The homogenate was centrifuged at 11,000 ϫ g for 10 min, and the pellet was rehomogenized and recentrifuged. The supernatant was filtered through cheesecloth and centrifuged at 100,000 ϫ g for 90 min. The pellet was resuspended in 0.3 M sucrose and 5 mM imidazole, pH 7.4, to a concentration of 3-5 mg/ml and layered onto a discontinuous sucrose gradient (27:32:38:45%) and centrifuged at 85,000 ϫ g for 16-18 hr in an SW28 rotor. The membranes at the 10:25%, 27:32%, 32:38%, and 38:45% interfaces were designated A, B, C, and D, respectively. All membranes were collected, diluted 1:4 with 10 mM imidazole pH 7.4, and centrifuged 80,000 ϫ g for 90 min. All pellets were rehomogenized in 0.3 M sucrose and 5 mM imidazole, pH 7.4, and stored at Ϫ80°.
A purified T tubule preparation was prepared as above except that the sucrose gradient consisted of 25:35:40:50%. The membranes at the 25:35, 35:40, and 40:50% interfaces were designated T tubules, light SR, and heavy SR, respectively. All membranes were collected, diluted 10-fold with 5 mM imidazole, pH 7.4, and centrifuged at 150,000 ϫ g for 30 min. Light SR and heavy SR were rehomogenized in 0.3 M sucrose and 5 mM imidazole, pH 7.4, and stored at Ϫ80°. The pellet containing T tubules was homogenized in 0.3 M sucrose and 5 mM imidazole, pH 7.4, in a glass-Teflon homogenizer and then incubated (0.1 mg/ml) in a solution containing 50 mM potassium phosphate, pH 7.4, 3 mM MgCl 2 , 0.15 M KCl, 0.3 mM CaCl 2 , and 2 mM MgATP for 20 min at room temperature. This incubation allowed any contaminating SR to be loaded with phosphate and separated from T tubules in the subsequent density gradient. After the incubation, the protein was centrifuged at 150,000 ϫ g for 30 min and resuspended in 2-3 ml of the loading solution. This solution was layered onto a second discontinuous sucrose gradient (35:50:63%) and centrifuged at 150,000 ϫ g for 75 min in an SW28 rotor. The layer at the 10:35% interface was collected and diluted 10-fold with 5 mM imidazole, pH 7.4, and recentrifuged at 150,000 ϫ g for 30 min. This final T tubule pellet was resuspended in 0.3 M sucrose and 5 mM imidazole, pH 7.4, and stored at Ϫ80°.
Enzyme marker assays. Analysis of Na ϩ /K ϩ -ATPase, Ca 2ϩ /K ϩ -ATPase, and azide-sensitive-ATPase was performed according to Jones and Besch (15) . Membranes used in the Na ϩ /K ϩ -ATPase assay were preincubated with 0.9 mg alamethicin/mg of membrane protein for 20 min at room temperature to unmask latent Na ϩ /K ϩ -ATPase activity. ATP blanks and phosphate standards were included to assess contaminating ATP in the reaction solutions and generate a standard curve.
The cholesterol content of membranes was determined using a cholesterol CII kit (Wako Biochemical Diagnostics, Edgewood, NJ).
After hydrolysis of cholesterol esters, cholesterol was oxidized to produce hydrogen peroxide, which was measured colorimetrically.
[ 3 H]P1075 binding assay. Assays were conducted in 12 ϫ 75-mm tubes in a total volume of 1 ml. The assay buffer consisted of 240 mM sucrose, 3 mM sodium orthovanadate, 2 mM MgCl 2 , and 50 mM Tris⅐HCl, pH 7.4 The nucleotides (sodium or trilithium salts), [ 3 H]P1075 (14 nM, 51-61 Ci/mmol), and inhibitors were incubated with membranes (700 g of rat brain, 50-200 g of rabbit skeletal muscle, 500-700 g of canine cardiac) for 60 (canine cardiac and rat brain) or 90 (skeletal muscle) min. Nonspecific binding was defined with 10 M P1075. Bound and free radioligands were separated by filtration through a GF/C glass-fiber filter on a Brandel (Montreal, Quebec, Canada) cell harvester with three 2-ml washes of 50 mM Tris, pH 7.4, at 4°. The filters were transferred to 6-ml plastic scintillation vials, soaked overnight in 5 ml of scintillation fluid (Opti-fluor; Packard, Meriden, CT), and counted in a Packard liquid scintillation counter.
Nucleotide metabolism assay. Skeletal muscle membranes (7 mg/ml in 50 mM Tris/240 mM sucrose/4 mM MgCl 2 ) were incubated at 25°in 1 ml of buffer (50 mM Tris⅐HCl, pH 7.4, 240 mM sucrose, 4 mM MgCl 2 , 2 mM ATP, 3 mM sodium orthovanadate) or an ATP regenerating system (1 mM dithiothreitol, 20 mM phosphocreatine, 10 units/ml creatine kinase, pH 7.4) or a system that removed enzymatically formed ATP (20 mM glucose, 15 units/ml hexokinase). The assay was initiated with the addition of membranes and stopped at appropriate times with the addition of 160 l of 3 M HClO 4 to achieve a final acid concentration of 3%. Each sample was then placed in ice and homogenized at 4°for 10 sec and centrifuged at 3000 rpm for 20 min at 4°. The supernatant was removed and neutralized with 1 ml of 2 M KHCO 3 . The neutralized samples were centrifuged at 3000 rpm for 20 min at 4°. The supernatants were removed, placed on ice, and filtered through a Millipore (Bedford, MA) 0.45-m HV filter. Separation of the nucleotides was achieved by reversed-phase ionpair chromatography on a Hewlett-Packard 1090 high performance liquid chromatograph equipped with a photodiode array detector and a Hewlett-Packard workstation computer interface. Samples (250 l) were applied to a C 18 218TP54 (250 ϫ 4.6 mm) 5-m column equilibrated in 30 mM KH 2 PO 4 , pH 5, 5 mM tetrabutylammonium dihydrogen phosphate, and 4% CH 3 CN (solvent A) at 1.5 ml/min. Nucleotides were eluted during a linear gradient of 0-35% solvent B (50% CH 3 CN) over 35 min. The nucleotides were detected at 254 nm, and their elution times were identified using ATP, ADP, AMP, UTP, UDP, and UMP standards. Nucleotide peaks, calculated as the integrated area under the curve, were obtained as in milliabsorption units and converted to micromoles from comparison of standard curves. There was base-line-to-base-line separation of the nucleotides, and as little as 50 nmol was readily detected. The identity of the compounds in the peaks was also confirmed by mass spectrometry analysis. Analysis of ATP, ADP, UTP, and UDP incubated without membranes indicated there was no appreciable degradation of the compounds during the time course of the experiment. Drugs. [ 3 H]P1075 was prepared in-house by catalytic tritiation of an olefinic precursor. Two tritium atoms were incorporated; the P1075 molecule and the resultant radioligand had a current specific activity of 51-61 Ci/mmol. The BMS compounds BMS-182264 [4- 
, and BMS-212345 [cis-1-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-3-phenylurea] were also synthesized in-house.
Calculations. K i values of competing drugs was calculated for IC 50 values according to the equation of Cheng and Prusoff (16) . Competition curves and saturation isotherms were analyzed to a four-parameter logistic equation using Sigma plot curve fitter, which fits data to nonlinear functions using the Marquardt-Levenberg algorithm. Goodness of fit to a one-or two-site binding model was determined by F test, in which
where SS is the sum of squares of residuals with one-versus two-site models and df is degrees of freedom of the corresponding models. Association rate constants (k ϩ1 ) were determined from pseudo-firstorder plots using the equation k ϩ1 ϭ k obs Ϫ k Ϫ1 /L, where k obs is the observed association rate constant, and L is the radioligand concentration. Dissociation rate constants were calculated from the firstorder plot of the dissociation reaction: k Ϫ1 ⅐t ϭ ln[X/X eq ], where X is the specific radioligand bound at time t, and X eq is the radioligand bound at equilibrium. The half-time values for dissociation reaction were calculated after linear regression analysis of this plot.
Results
Nucleotide regulation. Specific (Fig. 1B) . The effect of an ATP-regenerating system was therefore examined. Regeneration of ATP preserved stable ATP levels with little formation of ADP or AMP (Fig. 1C) . Under these conditions, a 10-fold leftward shift in the ATP dependency for [ 3 H]P1075 binding was observed (Fig. 1A) , and the calculated EC 50 value was 30 Ϯ 9 M with a slope factor of 1.7 Ϯ 0.3.
Maximal [
3 H]P1075 binding was decreased by 80% in the presence of the regenerating system. This decrease was due to the presence of creatine phosphate, which inhibited ATPsupported binding in a dose-dependent manner (data not shown). These data suggest that MgATP was responsible for specific [ 3 H]P1075 binding but endogenous hydrolases underestimated its potency.
To examine whether [ 3 H]P1075 binding supported by ADP was due to metabolically produced ATP, binding was measured in the absence and presence of a system that reconverted ATP formed from ADP back to ADP (using glucose and hexokinase). In the presence of this hexokinase regeneration system, there was no formation of ATP, but AMP was formed by ADPase (data not shown). Under these conditions, maximal [ 3 H]P1075 binding was decreased by 70 Ϯ 6%. Because the components of the hexokinase system had no effect on [ 3 H]P1075 binding, it was possible that as much as 70% of the ADP-supported binding resulted from ATP formed via transphosphorylation of added ADP.
Efforts to preserve NDP levels, by inhibiting ADPase, were unsuccessful because concentrations of inhibitors such as 5Ј-adenylylimido-diphosphate and trifluoperazine, which effectively inhibited ADPase activity, also decreased [ To examine the importance of phosphorylation for [ 3 H]P1075 binding, skeletal muscle membranes were treated with 100 units/ml calf alkaline phosphatase. This enzyme would be expected to dephosphorylate effector proteins. Binding supported by ATP or UTP was then measured. In the continued presence of alkaline phosphatase (during the binding reaction), [ 3 H]P1075 binding was eliminated by alkaline phosphatase treatment but unaffected by enzyme, which had been boiled. In contrast, membranes treated with enzyme Table 2 shows that binding was enriched in the P3 (100,000 ϫ g) membrane fraction, which had high levels of plasma membrane (Na ϩ /K ϩ -ATPase) and SR (Ca 2ϩ -ATPase) markers. [ 3 H]P1075 binding was not correlated with the activity of azide-sensitive ATPase or oligomycin-sensitive ATPase, a more specific mitochondrial marker (data not shown). Moreover, there was no enrichment of binding to a mitochondrial preparation of rabbit heart (data not shown). These data suggest that the membrane [ 3 H]P1075 binding sites were unlikely to be associated with mitochondria.
To examine the subcellular distribution in more detail, skeletal muscle membranes were fractionated to yield subcellular preparations enriched in specific organelles. Membranes that contained high activities of Ca 2ϩ -ATPase (300-600 mol/hr/mg of protein) had relatively low (Table 2 ). This fraction was not enriched for Ca 2ϩ -ATPase, Na ϩ /K ϩ -ATPase, or azide sensitive-ATPase. These data suggest that [ 3 H]P1075 binding sites were concentrated on T tubule-rich membranes.
Regional distribution. Specific [ 3 H]P1075 binding was also observed with guinea pig skeletal muscle, canine and rat one-site analysis. B, Adenine nucleotide metabolism by skeletal muscle membranes. Membranes were incubated with 2 mM ATP for the stated times under standard binding assay conditions. Formation of ADP (f) and AMP (‚) from added ATP (E) was determined using techniques described in Materials and Methods. C, Nucleotide metabolism was determined in the presence of an ATP-regeneration system, as described above. (Fig. 2) . Competition curves exhibited Hill slopes that were close to unity (0.8-1.2). Table 4 shows the structures of the fluoresceins and the position of substituents using the numbering system derived from the lactone form of the molecule. Fluorescein was a weak inhibitor of [ 
